Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P

被引:4
作者
Fukutomi, Motoki [1 ,2 ]
Tanaka, Nobuaki [2 ]
Uchinoumi, Hitoshi [2 ]
Kanemoto, Masashi [2 ]
Nakao, Fumiaki [2 ]
Yamada, Jutaro [3 ]
Kamei, Toshiaki [4 ]
Takenaka, Toshihiro [5 ]
Fujii, Takashi [2 ]
机构
[1] Yanai Municipal Heigun Clin, Yamaguchi, Japan
[2] Yamaguchi Grand Med Ctr, Dept Cardiol, Yamaguchi, Japan
[3] Yamaguchi Univ, Grad Sch Med, Dept Med & Clin Sci, Div Cardiol, Ube, Yamaguchi 7558505, Japan
[4] Yamaguchi Grand Med Ctr, Dept Pathol, Yamaguchi, Japan
[5] Kagoshima Univ, Grad Sch Med & Dent Sci, Div Cardiac Repair & Regenerat, Kagoshima 8908520, Japan
关键词
Fabry disease; Novel missense mutation; Left ventricular hypertrophy; Neurological manifestation; ALPHA-GALACTOSIDASE; REPLACEMENT THERAPY; GENE; SAFETY;
D O I
10.1016/j.jjcc.2013.02.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fabry disease, an X-linked lysosomal sphingolipid storage disorder caused by mutation of the a-galactosidase A (GLA) gene, results in systemic organ damage. However, the age of onset of clinical manifestations and course of the disease are variable even within the same family. Objective: In this study, we evaluated the clinical phenotype and the molecular lesions associated with the GLA gene in a Japanese family with Fabry disease that predominantly showed cardiac and neurological manifestations. Methods: A genetic analysis of the GLA gene using conventional genomic sequencing was performed in all seven members of this family, including four hemizygous males and three heterozygous females. Endomyocardial biopsy was performed in two patients with severe left ventricular (LV) hypertrophy. Results: A novel missense mutation was identified at codon 220 in exon 5, thus resulting in an arginine to proline substitution (R220P) in all seven family members. The three adult hemizygous males had LV hypertrophy and developed neurological manifestations in their 50 s. One of the adult hemizygotes developed complete atrioventricular block. On the other hand, we could not find any organ damage in a young hemizygous male or the three heterozygous females. Conclusion: We identified a novel missense mutation in a Japanese family with Fabry disease showing cardiac and neurological manifestations. In patients with Fabry disease, advanced organ damage in the heart and brain can be life-threatening, even if renal failure is lacking. (C) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 24 条
  • [1] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
    Banikazemi, Maryam
    Bultas, Jan
    Waldek, Stephen
    Wilcox, William R.
    Whitley, Chester B.
    McDonald, Marie
    Finkel, Richard
    Packman, Seymour
    Bichet, Daniel G.
    Warnock, David G.
    Desnick, Robert J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
  • [2] ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY
    BRADY, RO
    GAL, AE
    BRADLEY, RM
    MARTENSS.E
    WARSHAW, AL
    LASTER, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) : 1163 - &
  • [3] Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course
    Branton, MH
    Schiffmann, R
    Sabnis, SG
    Murray, GJ
    Quirk, JM
    Altarescu, G
    Goldfarb, L
    Brady, RO
    Balow, JE
    Austin, HA
    Kopp, JB
    [J]. MEDICINE, 2002, 81 (02) : 122 - 138
  • [4] Doi Y, 2003, Heart, V89, pe2, DOI 10.1136/heart.89.1.e2
  • [5] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16
  • [6] Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
    Germain, Dominique P.
    Giugliani, Roberto
    Hughes, Derralynn A.
    Mehta, Atul
    Nicholls, Kathy
    Barisoni, Laura
    Jennette, Charles J.
    Bragat, Alexander
    Castelli, Jeff
    Sitaraman, Sheela
    Lockhart, David J.
    Boudes, Pol F.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2012, 7
  • [7] Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
    Hughes, D. A.
    Elliott, P. M.
    Shah, J.
    Zuckerman, J.
    Coghlan, G.
    Brookes, J.
    Mehta, A. B.
    [J]. HEART, 2008, 94 (02) : 153 - 158
  • [8] IKARI Y, 1992, BRIT HEART J, V68, P323
  • [9] Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease
    Lee, Chyan-Jang
    Fan, Xin
    Guo, XiaoXin
    Medin, Jeffrey A.
    [J]. JOURNAL OF CARDIOLOGY, 2011, 57 (01) : 115 - 122
  • [10] Neurology of Fabry disease
    Low, M.
    Nicholls, K.
    Tubridy, N.
    Hand, P.
    Velakoulis, D.
    Kiers, L.
    Mitchell, P.
    Becker, G.
    [J]. INTERNAL MEDICINE JOURNAL, 2007, 37 (07) : 436 - 447